Intracranial Atherosclerotic Disease and Incident Dementia: The ARIC Study (Atherosclerosis Risk in Communities)

Di Zhao1, Eliseo Guallar1,2, Ye Qiao3

  • 1Department of Epidemiology, Bloomberg School of Public Health (D.Z., E.G.), Johns Hopkins University, Baltimore, MD.

Circulation
|August 1, 2024
PubMed

Insights

Intracranial atherosclerotic disease (ICAD) significantly increases dementia risk, independent of cerebral small vessel disease (CSVD) and other factors. This finding highlights ICAD as a crucial target for dementia prevention strategies.

Area of Science:

  • Neuroscience
  • Vascular Neurology
  • Epidemiology

Background:

  • Cerebral small vessel disease (CSVD) is a known contributor to dementia.
  • The impact of intracranial atherosclerotic disease (ICAD) on dementia risk in the general population is not well understood.
  • This study investigates the association between ICAD and incident dementia.

Purpose of the Study:

  • To determine the risk of developing dementia associated with intracranial atherosclerotic disease (ICAD).
  • To assess this risk while accounting for cerebral small vessel disease (CSVD) and common cardiovascular risk factors.
  • To explore the role of ICAD in dementia development within a US community-based cohort.

Main Methods:

  • Utilized brain MRI from 1980 participants in the Atherosclerosis Risk in Communities (ARIC) study.
  • Identified ICAD using high-resolution vessel wall MRI and MRA.
  • Assessed incident dementia over a median follow-up of 5.6 years using Cox proportional hazard models, adjusting for CSVD markers, APOE4, and cardiovascular risk factors.

Main Results:

  • Intracranial atherosclerotic disease (ICAD) was detected in 34.6% of participants.
  • ICAD was associated with a 57% increased risk of incident dementia (HR, 1.57; 95% CI, 1.17-2.11) after full adjustment.
  • Increased dementia risk was observed even with low-grade ICAD and in individuals with low CSVD burden.

Conclusions:

  • Intracranial atherosclerotic disease (ICAD) is an independent risk factor for incident dementia.
  • The findings suggest ICAD may mediate the impact of cardiovascular risk factors on cognitive decline.
  • Both ICAD and CSVD are critical considerations for understanding vascular contributions to dementia.
Abstract

Related Concept Videos

Arteries of the Head and Neck01:26

Arteries of the Head and Neck

The human body's intricate network of arteries ensures that every organ system receives the necessary oxygen and nutrients for optimal function. The arterial network in the head and neck region is particularly complex, providing vital blood flow to the brain, eyes, and other critical structures. Prominent arteries in this region include the internal carotid arteries and the vertebral arteries.
The internal carotid arteries supply blood to the anterior portion of the cerebrum. They enter the...
1.2K
The Arch of Aorta01:10

The Arch of Aorta

The coronary arteries, originating from the ascending aorta, bifurcate from two sinuses located within the ascending aorta. Positioned just above the aortic semilunar valve, these sinuses house essential aortic baroreceptors and chemoreceptors, crucial for maintaining cardiac function. The left coronary artery and the right coronary artery branch off from the left posterior and anterior aortic sinuses, respectively.
Encircling the heart, the coronary arteries form a ring-like structure before...
619
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
109
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172